WoodTrust Financial Corp Takes $6.77 Million Position in IDEXX Laboratories, Inc. $IDXX

WoodTrust Financial Corp purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 12,619 shares of the company’s stock, valued at approximately $6,768,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Mutual of America Capital Management LLC increased its position in shares of IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares during the last quarter. Golden State Wealth Management LLC increased its position in shares of IDEXX Laboratories by 3,766.7% in the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after purchasing an additional 113 shares during the last quarter. Plato Investment Management Ltd increased its position in shares of IDEXX Laboratories by 37.1% in the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after purchasing an additional 835 shares during the last quarter. Sagespring Wealth Partners LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $229,000. Finally, Genesis Wealth Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $215,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the sale, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the completion of the sale, the executive vice president owned 7,132 shares of the company’s stock, valued at $4,477,041.68. This trade represents a 54.11% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 4th. Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Finally, BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Stock Down 0.1%

Shares of NASDAQ:IDXX opened at $627.28 on Wednesday. The stock has a market cap of $50.18 billion, a P/E ratio of 52.23, a P/E/G ratio of 4.07 and a beta of 1.58. The firm has a fifty day moving average price of $636.83 and a 200 day moving average price of $538.44. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. IDEXX Laboratories’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.